Synthetic peptides that inhibit binding of the myelin basic protein 85-99 epitope to multiple sclerosis-associated HLA-DR2 molecules and MBP-specific T-cell responses
Identifieur interne : 003504 ( Main/Exploration ); précédent : 003503; suivant : 003505Synthetic peptides that inhibit binding of the myelin basic protein 85-99 epitope to multiple sclerosis-associated HLA-DR2 molecules and MBP-specific T-cell responses
Auteurs : Masha Fridkis-Hareli [États-Unis] ; Joel N. H Stern [États-Unis] ; Lars Fugger [Danemark] ; Jack L. Strominger [États-Unis]Source :
- Human Immunology [ 0198-8859 ] ; 2001.
English descriptors
- KwdEn :
- Teeft :
- Acad, Amino acids, Antigen presentation, Arnon, Assay, Binding motif, Binding motifs, Biotinylated, Cell clones, Clone, Copolymer, Crystal structure, Encephalomyelitis, Epitope, Final peptide concentration, Hafler, Histocompatibility, Hy1b, Immunodominant, Immunodominant epitope, Immunodominant myelin, Immunol, Inhibitor, Major histocompatibility, Methods section, Molecule, Multiple sclerosis, Myelin, Natl, Peptide, Polyclonal antibodies, Proc, Proc natl acad, Protein peptide, Random polypeptides, Sclerosis, Sela, Several peptides, Side chains, Sodium chloride, Strominger, Synthetic peptides, Teitelbaum, Unlabeled, Wucherpfennig.
Abstract
Abstract: Copolymer 1 (Cop 1, poly [Y, E, A, K]) is a random synthetic amino acid copolymer effective in the treatment of relapsing forms of multiple sclerosis (MS), a disease that is linked to HLA-DR2 (DRB1∗1501). In the present study various peptides, synthesized according to the binding motifs for both the immunodominant epitope of myelin basic protein (MBP) 85-99, a candidate autoantigen in MS, and Cop 1, differentially inhibited binding of these antigens to disease-associated HLA-DR2 (DRB1∗1501) molecules. In particular, two peptides with residue K at position P-1, as referred to MBP 85-99, inhibited effectively the binding of both biotinylated MBP 85-99 and Cop 1 to HLA-DR2 molecules as well as IL-2 production by two MBP-specific HLA-DR2-restricted T-cell clones. These findings suggest the possible utility of these compounds or their more stable derivatives in treatment of MS.
Url:
DOI: 10.1016/S0198-8859(01)00279-8
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000819
- to stream Istex, to step Curation: 000819
- to stream Istex, to step Checkpoint: 000E26
- to stream Main, to step Merge: 003542
- to stream Main, to step Curation: 003504
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Synthetic peptides that inhibit binding of the myelin basic protein 85-99 epitope to multiple sclerosis-associated HLA-DR2 molecules and MBP-specific T-cell responses</title><author><name sortKey="Fridkis Hareli, Masha" sort="Fridkis Hareli, Masha" uniqKey="Fridkis Hareli M" first="Masha" last="Fridkis-Hareli">Masha Fridkis-Hareli</name></author><author><name sortKey="Stern, Joel N H" sort="Stern, Joel N H" uniqKey="Stern J" first="Joel N. H" last="Stern">Joel N. H Stern</name></author><author><name sortKey="Fugger, Lars" sort="Fugger, Lars" uniqKey="Fugger L" first="Lars" last="Fugger">Lars Fugger</name></author><author><name sortKey="Strominger, Jack L" sort="Strominger, Jack L" uniqKey="Strominger J" first="Jack L" last="Strominger">Jack L. Strominger</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:0575E1F655B214465309154DC12F7A6C8421EFC7</idno><date when="2001" year="2001">2001</date><idno type="doi">10.1016/S0198-8859(01)00279-8</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-5QDQKMJM-F/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000819</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000819</idno><idno type="wicri:Area/Istex/Curation">000819</idno><idno type="wicri:Area/Istex/Checkpoint">000E26</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000E26</idno><idno type="wicri:doubleKey">0198-8859:2001:Fridkis Hareli M:synthetic:peptides:that</idno><idno type="wicri:Area/Main/Merge">003542</idno><idno type="wicri:Area/Main/Curation">003504</idno><idno type="wicri:Area/Main/Exploration">003504</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Synthetic peptides that inhibit binding of the myelin basic protein 85-99 epitope to multiple sclerosis-associated HLA-DR2 molecules and MBP-specific T-cell responses</title><author><name sortKey="Fridkis Hareli, Masha" sort="Fridkis Hareli, Masha" uniqKey="Fridkis Hareli M" first="Masha" last="Fridkis-Hareli">Masha Fridkis-Hareli</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Molecular and Cellular Biology (M.F.-H., J.N.H.S., J.L.S.), Harvard University, Cambridge, MA</wicri:regionArea><orgName type="university">Université Harvard</orgName><placeName><settlement type="city">Cambridge (Massachusetts)</settlement><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Stern, Joel N H" sort="Stern, Joel N H" uniqKey="Stern J" first="Joel N. H" last="Stern">Joel N. H Stern</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Molecular and Cellular Biology (M.F.-H., J.N.H.S., J.L.S.), Harvard University, Cambridge, MA</wicri:regionArea><orgName type="university">Université Harvard</orgName><placeName><settlement type="city">Cambridge (Massachusetts)</settlement><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Fugger, Lars" sort="Fugger, Lars" uniqKey="Fugger L" first="Lars" last="Fugger">Lars Fugger</name><affiliation wicri:level="1"><country xml:lang="fr">Danemark</country><wicri:regionArea>Department of Clinical Immunology (L. F.), Aarhus University Hospital, Skejby Sygehus, Aarhus N</wicri:regionArea><wicri:noRegion>Aarhus N</wicri:noRegion></affiliation></author><author><name sortKey="Strominger, Jack L" sort="Strominger, Jack L" uniqKey="Strominger J" first="Jack L" last="Strominger">Jack L. Strominger</name><affiliation wicri:level="1"><country wicri:rule="url">États-Unis</country></affiliation><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Molecular and Cellular Biology (M.F.-H., J.N.H.S., J.L.S.), Harvard University, Cambridge, MA</wicri:regionArea><orgName type="university">Université Harvard</orgName><placeName><settlement type="city">Cambridge (Massachusetts)</settlement><region type="state">Massachusetts</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Human Immunology</title><title level="j" type="abbrev">HIM</title><idno type="ISSN">0198-8859</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2001">2001</date><biblScope unit="volume">62</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="753">753</biblScope><biblScope unit="page" to="763">763</biblScope></imprint><idno type="ISSN">0198-8859</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0198-8859</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cop 1</term><term>HA</term><term>HLA-DR</term><term>MBP</term><term>MS</term><term>RA</term><term>T cells</term><term>peptides</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Acad</term><term>Amino acids</term><term>Antigen presentation</term><term>Arnon</term><term>Assay</term><term>Binding motif</term><term>Binding motifs</term><term>Biotinylated</term><term>Cell clones</term><term>Clone</term><term>Copolymer</term><term>Crystal structure</term><term>Encephalomyelitis</term><term>Epitope</term><term>Final peptide concentration</term><term>Hafler</term><term>Histocompatibility</term><term>Hy1b</term><term>Immunodominant</term><term>Immunodominant epitope</term><term>Immunodominant myelin</term><term>Immunol</term><term>Inhibitor</term><term>Major histocompatibility</term><term>Methods section</term><term>Molecule</term><term>Multiple sclerosis</term><term>Myelin</term><term>Natl</term><term>Peptide</term><term>Polyclonal antibodies</term><term>Proc</term><term>Proc natl acad</term><term>Protein peptide</term><term>Random polypeptides</term><term>Sclerosis</term><term>Sela</term><term>Several peptides</term><term>Side chains</term><term>Sodium chloride</term><term>Strominger</term><term>Synthetic peptides</term><term>Teitelbaum</term><term>Unlabeled</term><term>Wucherpfennig</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Copolymer 1 (Cop 1, poly [Y, E, A, K]) is a random synthetic amino acid copolymer effective in the treatment of relapsing forms of multiple sclerosis (MS), a disease that is linked to HLA-DR2 (DRB1∗1501). In the present study various peptides, synthesized according to the binding motifs for both the immunodominant epitope of myelin basic protein (MBP) 85-99, a candidate autoantigen in MS, and Cop 1, differentially inhibited binding of these antigens to disease-associated HLA-DR2 (DRB1∗1501) molecules. In particular, two peptides with residue K at position P-1, as referred to MBP 85-99, inhibited effectively the binding of both biotinylated MBP 85-99 and Cop 1 to HLA-DR2 molecules as well as IL-2 production by two MBP-specific HLA-DR2-restricted T-cell clones. These findings suggest the possible utility of these compounds or their more stable derivatives in treatment of MS.</div></front></TEI><affiliations><list><country><li>Danemark</li><li>États-Unis</li></country><region><li>Massachusetts</li></region><settlement><li>Cambridge (Massachusetts)</li></settlement><orgName><li>Université Harvard</li></orgName></list><tree><country name="États-Unis"><region name="Massachusetts"><name sortKey="Fridkis Hareli, Masha" sort="Fridkis Hareli, Masha" uniqKey="Fridkis Hareli M" first="Masha" last="Fridkis-Hareli">Masha Fridkis-Hareli</name></region><name sortKey="Stern, Joel N H" sort="Stern, Joel N H" uniqKey="Stern J" first="Joel N. H" last="Stern">Joel N. H Stern</name><name sortKey="Strominger, Jack L" sort="Strominger, Jack L" uniqKey="Strominger J" first="Jack L" last="Strominger">Jack L. Strominger</name><name sortKey="Strominger, Jack L" sort="Strominger, Jack L" uniqKey="Strominger J" first="Jack L" last="Strominger">Jack L. Strominger</name></country><country name="Danemark"><noRegion><name sortKey="Fugger, Lars" sort="Fugger, Lars" uniqKey="Fugger L" first="Lars" last="Fugger">Lars Fugger</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003504 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003504 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:0575E1F655B214465309154DC12F7A6C8421EFC7
|texte= Synthetic peptides that inhibit binding of the myelin basic protein 85-99 epitope to multiple sclerosis-associated HLA-DR2 molecules and MBP-specific T-cell responses
}}
| This area was generated with Dilib version V0.6.33. |  |